Concert Pharmaceuticals Announces Closing of Public Offering & Full Exercise of Underwriters’ Option to Purchase Additional...
30 Enero 2020 - 3:01PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the
closing of its previously announced underwritten public offering of
5,735,283 shares of its common stock to the public at $9.92 per
share, which included the full exercise of the underwriters’ option
to purchase 982,863 additional shares of common stock. In addition,
and in lieu of common stock, Concert sold to a certain existing
investor pre-funded warrants to purchase up to an aggregate of
1,800,000 shares of common stock at a purchase price of $9.919 per
pre-funded warrant, which represents the per share public offering
price for the common stock less the $0.001 per share exercise price
for each pre-funded warrant. The aggregate gross proceeds to
Concert from this offering were approximately $74.7 million, before
deducting underwriting discounts and commissions and other offering
expenses payable by Concert.
Jefferies acted as sole book-running manager for the offering.
Mizuho Securities and JMP Securities acted as lead managers, and
H.C. Wainwright & Co. acted as co-manager for the offering.
The offering was made only by means of a written prospectus
supplement and prospectus forming part of a shelf registration
statement previously filed with the Securities and Exchange
Commission (SEC) and declared effective on March 7, 2018. The final
prospectus supplement and accompanying prospectus relating to the
offering was filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus may also be obtained by contacting
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
(877) 821-7388, or by email at
prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
other jurisdiction.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to treat
serious diseases and address unmet patient needs. The Company’s
approach starts with previously studied compounds, including
approved drugs, in which deuterium substitution has the potential
to enhance clinical safety, tolerability or efficacy. Concert’s
pipeline of innovative medicines targets autoimmune diseases and
central nervous systems (CNS) disorders.
Cautionary Note on Forward Looking Statements
Any statements in this press release about the anticipated net
proceeds from the offering and other statements containing the
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “would” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
higher than expected offering expenses, market and other
conditions, and other factors discussed in the “Risk Factors”
section of our most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, in the final prospectus
supplement related to the offering filed with the Securities and
Exchange Commission on January 28, 2020 and in other filings that
we make with the Securities and Exchange Commission. In addition,
any forward-looking statements included in this press release
represent our views only as of the date of this release and should
not be relied upon as representing our views as of any subsequent
date. We specifically disclaim any obligation to update any
forward-looking statements included in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200130005721/en/
Justine Koenigsberg (investors) Concert Pharmaceuticals, Inc.
(781) 674-5284 ir@concertpharma.com
Barbara Yates (media) The Yates Network (781) 258-6153
barbara@theyatesnetwork.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024